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COMMENTARY
Inflammation resolution: a dual-pronged approach to averting
cytokine storms in COVID-19?
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Abstract
Severe coronavirus disease (COVID-19) is characterized by pulmonary hyper-inflammation and potentially life-threatening
“cytokine storms”. Controlling the local and systemic inflammatory response in COVID-19 may be as important as anti-viral
therapies. Endogenous lipid autacoid mediators, referred to as eicosanoids, play a critical role in the induction of inflammation
and pro-inflammatory cytokine production. SARS-CoV-2 may trigger a cell death (“debris”)-induced “eicosanoid storm”,
including prostaglandins and leukotrienes, which in turn initiates a robust inflammatory response. A paradigm shift is emerging
in our understanding of the resolution of inflammation as an active biochemical process with the discovery of novel endogenous
specialized pro-resolving lipid autacoid mediators (SPMs), such as resolvins. Resolvins and other SPMs stimulate macrophage-
mediated clearance of debris and counter pro-inflammatory cytokine production, a process called inflammation resolution. SPMs
and their lipid precursors exhibit anti-viral activity at nanogram doses in the setting of influenza without being immunosuppres-
sive. SPMs also promote anti-viral B cell antibodies and lymphocyte activity, highlighting their potential use in the treatment of
COVID-19. Soluble epoxide hydrolase (sEH) inhibitors stabilize arachidonic acid-derived epoxyeicosatrienoic acids (EETs),
which also stimulate inflammation resolution by promoting the production of pro-resolution mediators, activating anti-inflam-
matory processes, and preventing the cytokine storm. Both resolvins and EETs also attenuate pathological thrombosis and
promote clot removal, which is emerging as a key pathology of COVID-19 infection. Thus, both SPMs and sEH inhibitors
may promote the resolution of inflammation in COVID-19, thereby reducing acute respiratory distress syndrome (ARDS) and
other life-threatening complications associated with robust viral-induced inflammation. While most COVID-19 clinical trials
focus on “anti-viral” and “anti-inflammatory” strategies, stimulating inflammation resolution is a novel host-centric therapeutic
avenue. Importantly, SPMs and sEH inhibitors are currently in clinical trials for other inflammatory diseases and could be rapidly
translated for the management of COVID-19 via debris clearance and inflammatory cytokine suppression. Here, we discuss using
pro-resolution mediators as a potential complement to current anti-viral strategies for COVID-19.
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Severe coronavirus disease (COVID-19) caused by the
SARS-CoV-2 virus is frequently characterized by pulmonary
inflammation [1]. Life-threatening “cytokine storms” involv-
ing the release of pro-inflammatory cytokines (e.g., TNF-α,
IL-6, IL-1, IL-8, and MCP-1) may contribute to the rapid
systemic organ failure observed in select critically ill
COVID-19 patients [1]. However, this storm is not a self-
limiting, singular event. SARS-CoV-2 causes massive cell
death and cellular debris that activates inflammasomes [2],
which in turn trigger a macrophage-derived “eicosanoid
storm”, a surge of pro-inflammatory bioactive lipid mediators,
such as prostaglandins and leukotrienes, that fuels local in-
flammation [3–5]. A paradigm shift in the inflammation field
is that the resolution of inflammation is an active biochemical
process [5], implying that hyper-inflammation may result
from a deficit in resolution.
In contrast to classic anti-inflammatory agents, endogenous
pro-resolution lipids can terminate the inflammatory response
by promoting the clearance of cellular debris. Specialized pro-
resolving mediators (SPMs), including resolvins, lipoxins,
and protectins, are bioactive lipid autacoids that mediate
endogenous resolution by stimulating macrophage phagocy-
tosis of cellular debris and countering the release of pro-
inflammatory cytokines/chemokines [5]. Importantly, loss of
inflammation resolutionmechanisms plays a role in sustaining
pathologic inflammation [5]. Endogenous resolution process-
es have been identified in the termination of infectious dis-
eases [5], including influenza [6–8], and could thus be
harnessed for averting dysregulated inflammation and associ-
ated mortality in COVID-19. SPMs promote anti-viral B lym-
phocytic activity in influenza [7], suggesting they may be a
promising therapy for COVID-19. SPM precursors including
17-hydroxydocosahexaenoic acid (17-HDHA) have also been
identified as potentially promising vaccine adjuvants as they
protect against primary influenza infection and promote adap-
tive immunity [7, 8]. Thus, the use of SPMs or their precursors
in combination with COVID-19 vaccines may be a novel and
effective therapeutic approach.
The resolution of inflammation is also stimulated by another
pathway involving arachidonic acid–derived epoxyeicosatrienoic
acids (EETs). These mediators promote clearance of cellular de-
bris and activate anti-inflammatory programs to inhibit several
Fig. 1 Inflammation resolution in severe COVID-19 infection. The left
alveolus demonstrates (1) viral-induced alveolar cell death and the accu-
mulation of apoptotic and necrotic cellular debris. This debris elicits a pro-
inflammatory response from macrophages (2), which in turn produce high
quantities of eicosanoids generating an “eicosanoid storm”. These eicosa-
noids subsequently stimulate the production of pro-inflammatory cyto-
kines (3) by immune cells such as macrophages, generating a robust “cy-
tokine storm” that in turn promotes further leukocytosis and immune cell
infiltrates (4). This robust inflammatory response to viral infection pro-
motes hyaline membrane formation (5) and subsequent acute respiratory
distress syndrome. Tissue levels of SPMs and EETs are decreased in this
robust inflammatory setting. The right alveolus demonstrates COVID-19
infection in the setting of active inflammation resolution mechanisms, as is
the case in mild infection or potentially following treatment with SPMs or
sEH inhibition to increase EETs. EETs promote the generation of SPMs
from arachidonic acid and omega-3 fatty acids. SPMs (1) stimulate mac-
rophage phagocytosis and efferocytosis, (2) decrease pro-inflammatory
cytokine production, (3) inhibit leukocytosis and thereby decrease the
inflammatory infiltrate, and (4) may stimulate the adaptive immune re-
sponse and the production of anti-SARS-CoV-2 antibodies
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key pro-inflammatory cytokines [9, 10]. EETs and other epoxy
fatty acids specifically promote production of SPMs, such as
lipoxins, by shifting arachidonic acid metabolism to favor in-
flammation resolution [11]. As EETs are rapidly metabolized
by soluble epoxide hydrolase (sEH), administration of sEH in-
hibitors (sEHIs) can stabilize EET levels, prevent lung inflam-
mation, and improve lung function in animal models, making
them an attractive potential therapeutic strategy for COVID-19.
Both SPMs and sEHIs downregulate the transcription regulator
NF-κB [5, 11], the center of eicosanoid-induced cytokine storms,
which promotes the induction of pro-inflammatory cytokines
and prostaglandin synthesis via cyclooxygenase (COX).
Combined pharmacological abrogation of COX-2 and sEH ac-
tivity also prevents cytokine and eicosanoid storms via debris
clearance mechanisms [4], offering another promising therapeu-
tic intervention.
Targeting individual pro-inflammatory cytokines may not
be sufficient to prevent COVID-19 progression. Importantly,
SPMs terminate self-sustaining inflammatory processes, such
as those induced by COVID-19, by broadly inhibiting pro-
inflammatory cytokine production and promoting a return to
tissue homeostasis [5, 7, 8]. In contrast to some anti-
inflammatory agents, which may be contraindicated in
COVID-19 patients, SPMs and sEHIs act at significantly low-
er doses and are not immunosuppressive [5, 11]. Moreover,
conventional anti-inflammatory agents such as NSAIDs and
COX-2 inhibitors, while limiting the eicosanoid storm, may
be “resolution toxic” as they indiscriminately inhibit eicosa-
noid pathways that produce resolution mediators and thereby
prevent active resolution [5]. Inhibiting resolution mediator
production may potentially facilitate COVID-19-induced tis-
sue injury and progression of infection. As demonstrated in
many inflammatory disease models, selectively promoting en-
dogenous inflammation resolution mechanisms clears inflam-
matory exudates more effectively and promotes a return to
tissue homeostasis compared with classic anti-inflammatory
agents [5–11].
Most COVID-19 clinical trials focus on “anti-viral” and “an-
ti-inflammatory” strategies. In contrast, stimulation of inflam-
mation resolution is a novel host-focused alternative to comple-
ment current therapies. The loss of active resolution mecha-
nisms [5] and dysregulation of SPMs and EETs in sustained
pathological inflammation and lung diseases present a new op-
portunity for the management of COVID-19. Pro-resolvingme-
diators, as well as sEH blockade, may resolve the potentially
fatal cytokine storm and severe pulmonary inflammation in
COVID-19 patients (see Fig. 1). Importantly, both SPMs and
EETs have also been shown to attenuate pathologic thrombosis
and promote clot removal, which is now recognized as a key
pathology of COVID-19 infection [12–14]. SPMs including
resolvins, lipoxins, and protectins, as well as sEHIs, are current-
ly in clinical trials for other inflammatory diseases and could be
rapidly translated for the management of COVID-19 by
complementing current anti-viral strategies via debris clearance
and inflammatory cytokine suppression. Thus, activating en-
dogenous resolution pathways may be a novel therapeutic ap-
proach to limit severe organ damage and improve outcomes in
COVID-19 patients.
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